This report studies Benign Prostatic Hyperplasia (BPH) Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Astellas Pharma Eli Lilly GlaxoSmithKline Sanofi ADC Therapeutics Advaxis Agennix ANI Pharmaceuticals BHR Pharma Bristol-Myers Squibb Boehringer Ingelheim Dendreo Endo Pharmaceuticals By types, the market can be split into Alpha-blocker Phosphodiesterase type-5 inhibitors 5-alpha-Reductase inhibitors By Application, the market can be split into Clinical medicine Scientific research Others By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India
Table of Contents Global Benign Prostatic Hyperplasia (BPH) Drugs Market Professional Survey Report 2017 1 Industry Overview of Benign Prostatic Hyperplasia (BPH) Drugs 1.1 Definition and Specifications of Benign Prostatic Hyperplasia (BPH) Drugs 1.1.1 Definition of Benign Prostatic Hyperplasia (BPH) Drugs 1.1.2 Specifications of Benign Prostatic Hyperplasia (BPH) Drugs
